rituximab + cyclophosphamide + vincristine + doxorubicin + methotrexate + etoposide + methylprednisolone

This multi-agent chemo-immunotherapy regimen serves as the induction phase of a clinical protocol developed by Andres J. M. Ferreri for the treatment of HIV-positive patients with Burkitt lymphoma. The regimen is an intensive, short-term combination designed to achieve rapid cytoreduction and complete response in a population traditionally considered high-risk due to immunosuppression. It incorporates the anti-CD20 monoclonal antibody rituximab alongside a complex cytotoxic backbone consisting of cyclophosphamide, vincristine, doxorubicin, methotrexate, and etoposide, supplemented by the corticosteroid methylprednisolone. This approach leverages highly active antiretroviral therapy (HAART) to allow HIV-positive patients to tolerate dose-intensive chemotherapy similar to immuno-competent patients. The protocol is structured such that subsequent treatment (consolidation or intensification) is determined by the objective response observed at the end of this induction phase.

Other names

induction phase-Andres J. M. Ferreri-Burkitt lymphomaInduction Phase (Andres J. M. Ferreri protocol)Short-term intensified chemo-immunotherapy